We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Luminex Poised on Pipeline Strength, System Sales Upbeat
Read MoreHide Full Article
On Aug 29, we issued an updated research report on Austin-based Luminex Corp – a manufacturer and marketer of proprietary biological testing technologies with applications throughout the life sciences and diagnostics industry. The company currently carries a Zacks Rank #3 (Hold).
Notably, after posting impressive second-quarter fiscal 2016 results, Luminex is currently well positioned on its pipeline strength that includes an exclusive range of assays and the company’s flagship Aries M1 platform.
In this connection, a glimpse at the second-quarter results reveals that Luminex generated strong revenues and adjusted earnings per share, beating the Zacks Consensus Estimate on both lines.
Additionally, solid system sales, which registered significant year-over-year growth in the reported quarter, is a key catalyst for the company’s impressive market position.
Apart from the lucrative promises held by the company’s systems and assay portfolios, the collaboration with Nanosphere is another significant growth driver. Particularly, the Verigene System of Nanosphere is likely to significantly enhance Luminex’s growth trajectory in the coming quarters, in our view.
However, on the flip side, the volatility that persists with the departure of LabCorp, a blurry reimbursement landscape, inventory management problems at Luminex’s largest customer, and reduction in ‘Medicare reimbursement Rate’ are the major stock dampeners.
Luminex also expects consumer revenues to decline in the second half of the year, but still represent modest growth (close to 10%) for the full year.
In this regard, we note that, over the last 30 days, the Zacks Consensus Estimate for full-year 2016 earnings declined by 20 cents to 61 cents per share, as most analysts revised their estimates downward.
Stocks to Consider
Some better-ranked stocks in the broader medical space include Masimo Corporation (MASI - Free Report) , Quidel Corp. (QDEL - Free Report) and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Luminex Poised on Pipeline Strength, System Sales Upbeat
On Aug 29, we issued an updated research report on Austin-based Luminex Corp – a manufacturer and marketer of proprietary biological testing technologies with applications throughout the life sciences and diagnostics industry. The company currently carries a Zacks Rank #3 (Hold).
Notably, after posting impressive second-quarter fiscal 2016 results, Luminex is currently well positioned on its pipeline strength that includes an exclusive range of assays and the company’s flagship Aries M1 platform.
In this connection, a glimpse at the second-quarter results reveals that Luminex generated strong revenues and adjusted earnings per share, beating the Zacks Consensus Estimate on both lines.
Additionally, solid system sales, which registered significant year-over-year growth in the reported quarter, is a key catalyst for the company’s impressive market position.
LUMINEX CORP Price and Consensus
LUMINEX CORP Price and Consensus | LUMINEX CORP Quote
Apart from the lucrative promises held by the company’s systems and assay portfolios, the collaboration with Nanosphere is another significant growth driver. Particularly, the Verigene System of Nanosphere is likely to significantly enhance Luminex’s growth trajectory in the coming quarters, in our view.
However, on the flip side, the volatility that persists with the departure of LabCorp, a blurry reimbursement landscape, inventory management problems at Luminex’s largest customer, and reduction in ‘Medicare reimbursement Rate’ are the major stock dampeners.
Luminex also expects consumer revenues to decline in the second half of the year, but still represent modest growth (close to 10%) for the full year.
In this regard, we note that, over the last 30 days, the Zacks Consensus Estimate for full-year 2016 earnings declined by 20 cents to 61 cents per share, as most analysts revised their estimates downward.
Stocks to Consider
Some better-ranked stocks in the broader medical space include Masimo Corporation (MASI - Free Report) , Quidel Corp. (QDEL - Free Report) and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>